P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY

• A. Brunner,
• Y. Liu,
• L. Mendez,
• J. Garcia,
• P. Amrein,
• D. Neuberg,
• E. Dean,
• S. Smith,
• R. Stone,
• A. Fathi,
• M. Walter,
• T. Graubert,
• M. Jacoby

Affiliations

A. Brunner

1 Massachusetts General Hospital

Y. Liu

2 Dana-Farber Cancer Institute

L. Mendez

3 Beth-Israel Deaconess Medical Center, Boston, United States of America

J. Garcia

2 Dana-Farber Cancer Institute

P. Amrein

1 Massachusetts General Hospital

D. Neuberg

2 Dana-Farber Cancer Institute

E. Dean

4 AstraZeneca, Cambridge, United Kingdom

S. Smith

4 AstraZeneca, Cambridge, United Kingdom

R. Stone

2 Dana-Farber Cancer Institute

A. Fathi

1 Massachusetts General Hospital

M. Walter

5 Washington University School of Medicine, St. Louis, United States of America

T. Graubert

1 Massachusetts General Hospital

M. Jacoby

5 Washington University School of Medicine, St. Louis, United States of America